-
Featured
Treatments for Benign Prostatic Hyperplasia
Current treatments generally focus on oral medications or invasive surgery, which can have side effects. The prostatic urethral lift and water steam therapy are effective, non-invasive treatments for BPH.
-
Featured
Multiparametric MRI/Ultrasound Fusion Biopsy Improves Prostate Cancer Detection
Active surveillance (AS) has become an accepted way to manage prostate cancer in men at lower risk. Multiparametric MRI can be used in conjunction with the standard transrectal ultrasound (TRUS)-guided biopsy to improve detection of clinically significant cancers.
-
Featured
BPH Supplements Have Little Support for Efficacy and Safety
To better advise patients about herbal remedies for prostate enlargement or benign prostatic hyperplasia (BPH), researchers scoured the scientific literature for evidence on every individual ingredient of every available supplement.
-
Case Series: Mucinous Adenocarcinoma of the Prostatic Urethra After Brachytherapy for Prostatic Adenocarcinoma
Massachusetts General Hospital researchers present the first case series of brachytherapy-associated mucinous adenocarcinoma of the prostatic urethra, reviewing clinical and pathologic differences from its radiation-independent counterpart and concluding it's associated with lower stage and less aggressive behavior.
-
Predicted Survival After Radical Prostatectomy Varied by Race With a Trained Machine Classifier
Using a U.S. cancer database, Madhur Nayan, MDCM, PhD, and colleagues trained a machine-learning algorithm to predict survival after radical prostatectomy in race-specific subgroups. Nevertheless, the algorithm overestimated the survival of patients whose race was not listed as white or African American.
-
Combination Prostate Biopsy Can Overestimate Gleason Grade Compared with Surgical Pathology
By studying men who underwent both standard prostate biopsy and MRI–ultrasound targeted biopsy, Adam S. Feldman, MD, MPH, of the Department of Urology, and colleagues determined combination biopsy can overestimate Gleason grade compared to surgical pathology, presenting a risk of overtreatment.
Prostate Contributors
-
Adam Scott Feldman, MD, MPH
Director, Combined Harvard Urologic Oncology Fellowship, Director of Research and Urologic Oncologist, Department of Urology, Massachusetts General Hospital
Recent Article
Review: Active Surveillance for Intermediate-risk Prostate Cancer
-
Douglas Middleton Dahl, MD
Chief, Division of Urologic Oncology, Director of Robotic Surgery, Massachusetts General Hospital, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Genetic Signature Predicts Metastasis, Survival in Clear Cell Renal Cell Carcinoma
-
-
Jason A. Efstathiou, MD, DPhil
Vice-Chair, Faculty & Academic Affairs, Director, Genitourinary Service, Department of Radiation Oncology, Clinical Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers Multidisciplinary Clinic, Massachusetts General Hospital
Recent Article
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation -
Matthew F. Wszolek, MD
Chair of Quality and Safety, Department of Urology, Massachusetts General Hospital, Urological Oncologist, Mass General Cancer Center, Instructor in Surgery, Harvard Medical School
Recent Article
Advancing Trimodality Therapy for Bladder Cancer
-
Mukesh G. Harisinghani, MD
Director, Abdominal MRI, Department of Radiology, Massachusetts General Hospital
Recent Article
Review: Advances in Radiologic Staging of Colorectal Cancer
-
Shahin Tabatabaei, MD
Director, Prostate Health Program
Recent Article
BPH Supplements Have Little Support for Efficacy and Safety
Urology Care at Mass General
The Department of Urology at Massachusetts General Hospital offers sophisticated, compassionate care and the most innovative treatments for patients with any type of urological condition.